US Clinical Trials Market

The United States Clinical Trials market segmentation, based on phase, includes Phase 1, Phase 2, Phase 3, and Phase 4. The Phase 3 segment dominated the market mostly. This market has grown as a result of a number of factors, including the use of advanced services to evaluate the safety and efficacy of the drug candidates and a larger patient population for clinical research than for other stages.

Furthermore, phase 3 clinical studies are regarded as sophisticated clinical trials that call for dependable clinical resources in addition to strong technology in order to successfully recruit patients, establish locations swiftly, and offer cost-effective study management.

The United States Clinical Trials market segmentation, based on study design, includes Observational, Interventional, and Expanded Access. The interventional category generated the most income. The effectiveness of new intermediation can be measured more accurately and with comparatively more evidence when using interventional studies. This is why a lot of biologics and medications are the subject of them. Another benefit of an interventional study is the reduced recall bias, which occurs when exposure information is obtained before the onset of the disease.

Figure 1: United States Clinical Trials Market, by Study Design, 2023 & 2032 (USD Billion)

The United States Clinical Trials market segmentation, based on application, includes Vaccine, Cell & Gene Therapy, Small Molecules, and Other Applications. The cell & gene therapy category generated the most income, propelled by improvements in investment, biotechnology, and the potential to treat a vast range of illnesses. This expansion is driven by the possibility that new therapies may offer individualized care and possibly even cures for illnesses that were incurable before. Furthermore, regulatory bodies are becoming more helpful, hastening the approval process for novel treatments.

The United States Clinical Trials market segmentation, based on indication, includes Autoimmune/Inflammation (Rheumatoid arthritis, Multiple Sclerosis, Osteoarthritis, Irritable Bowel Syndrome (IBS), Others), Pain Management (Chronic Pain, Acute Pain), Oncology (Blood Cancer, Solid Tumors, Other), CNS Condition (Epilepsy, Parkinson's Disease (PD), Huntington's Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Muscle Regeneration, Others), Diabetes, Obesity, Cardiovascular, and Others. The oncology category generated the most income. The growing number of older people and the rising incidence of cancer are factors driving the growth of the market in the oncology sector.

The US is expected to see 609,820 cancer fatalities and 1,958,310 new instances of cancer in 2023, according to estimates from the American Cancer Society. There is a large unmet medical need for treatments for primary malignancies (e.g., prostate, lung, breast, and colon cancer) despite the tremendous advancements in cancer diagnosis, prevention, and treatment methods. This is probably going to lead to more activity in cancer research and development.

The United States Clinical Trials market segmentation, based on sponsor, includes Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, and Others. The pharmaceutical & biopharmaceutical companies category generated the most income. The pharmaceutical and biopharmaceutical companies segment contributed the most and is expected to continue leading the way throughout the forecast period. This is attributed to the expansion of these companies and the efforts made by public and private entities to advance the pharmaceutical industry.

The United States Clinical Trials market segmentation, based on service type, includes Protocol Designing, Patient Recruitment, Laboratory Services, Site Identification, Bioanalytical Testing Services (Cell-based Assays, Virology Testing, Method Development, Optimization, & Validation, Serology, Immunogenicity, & Neutralizing Antibodies, Biomarker Testing Services, PK/PD (Pharmacokinetics/Pharmacodynamics) Testing Services, Other Bioanalytical Testing Services), Analytical Testing Services, Clinical Trial Supply & Logistic Services, Clinical Trial Data Management Services, Decentralized Clinical Services, Medical Device Testing Services, and Others. The laboratory services category generated the most income.

It is anticipated that the growing significance of laboratory services in establishing regulatory compliance will spur the segment's expansion during the forecast period. Throughout the whole drug development process, including clinical advancement, laboratory services are essential.

The United States Clinical Trials market segmentation, based on end-user, includes Hospital, Laboratories, and Clinics. The laboratories category generated the most income. The growing incidence of chronic diseases necessitating extensive testing, the rise of pharmaceutical and biotechnology companies, and technological advancements are a few of them. Precision medicine is required more frequently. Further driving this market's expansion has been pharmaceutical corporations' outsourcing of laboratory services to specialist contract research organizations (CROs).

The United States' growth is ascribed to the growing pharmaceutical business, which is expected to boost industry revenue by concentrating on creating new medications to treat a range of chronic ailments. Due to the aging population's increased likelihood of developing a variety of chronic illnesses and age-related disorders, it is also expected that demand for pharmaceuticals, medical equipment, and therapeutic interventions will rise. Statistics on the market will rise as a result. For instance, the United States Census Bureau estimates that there were 54 million persons over 65 in the United States in 2019.

That number is expected to rise to approximately 98.2 million by the end of 2060. Businesses are, therefore, generally increasing their R&D expenditures. Furthermore, demand is expected to rise due to the United States government's significant support of clinical research. In March 2020, the FDA launched the Coronavirus Treatment Acceleration Program (CTAP) to expedite the development of medications for diseases caused by the coronavirus globally. Using all available resources, the program rapidly offers patients cutting-edge treatments while assessing their potential risks and benefits.